Vaccination programs have had a revolutionary impact on global public health, not only leading to dramatic reductions in the incidence of infectious diseases but also reducing childhood and adult mortality and improving the quality of life worldwide. Individuals can receive a wide range of vaccinations throughout their life to prevent infections and diseases associated with long-term chronic infections. Although vaccination guidelines may offer strong recommendations for certain vaccines, other vaccines are administered at the discretion of the prescribing physician and the patient. As such, commercial opportunity exists for vaccines that can offer meaningful advantages over current agents. Both the adult and pediatric segments of the vaccines market remain attractive areas for the development of new prophylactic options. This content will include coverage of current and emerging vaccines for key infectious diseases such as HPV, HZ, HBV, meningococcus, pneumococcus, seasonal influenza, RSV, and COVID-19. This content will also assess the impact of the COVID-19 pandemic on the vaccines market.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Geographies: United States, EU5, Japan
Primary research: Approximately 15 country-specific interviews with thought-leading infectious disease specialists; supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed events of emerging vaccines by country, segmented by key infectious diseases (HPV, HZ, meningococcus, pneumococcus, seasonal influenza, HBV, RSV, COVID-19).
Forecast: 10-year, annualized, vaccine-level sales and patient share of key vaccines through 2032, segmented by vaccines, geography, and key indications.
Emerging therapies: Registered / preregistered: 5+; Phase 3: 10+; Phase 2: 20+
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.